Disease · HP_0100607
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) vs Ethinyl Estradiol, Levonorgestrel (Miranova): serious adverse events | 2 of 234 | 2 of 230 | 464 | NCT00909857 | Trial comparisons |
| DRSP 3 mg/EE 20 µg (13 Cycles) vs DRSP 3 mg/EE 30 µg (6 Cycles): serious adverse events | 5 of 355 | 0 of 65 | 420 | NCT00461305 | Trial comparisons |
| DRSP 3 mg/EE 20 µg (6 Cycles) vs DRSP 3 mg/EE 30 µg (6 Cycles): Number of Participants With Intracyclic Bleeding at Cycle 6 | 40 of 299 | 4 of 56 | 355 | NCT00461305 | Trial comparisons |
| Active vs Placebo: serious adverse events | 0 of 77 | 0 of 77 | 154 | NCT00651313 | Trial comparisons |
| Study Group (CCOCP) vs Control Group (Traditional OCP): deaths from any cause | 0 of 19 | 0 of 19 | 38 | NCT00517556 | Trial comparisons |
| Study Group (CCOCP) vs Control Group (Traditional OCP): serious adverse events | 0 of 19 | 0 of 19 | 38 | NCT00517556 | Trial comparisons |
| ENG-E2 125 μg/300 μg vs Placebo: Number of Participants Who Experienced an Adverse Event (AE) | 1 of 13 | 2 of 11 | 24 | NCT02668783 | Trial comparisons |
| ENG-E2 125 μg/300 μg vs Placebo: Number of Participants Who Discontinued Treatment Due to an AE | 0 of 13 | 0 of 11 | 24 | NCT02668783 | Trial comparisons |
| ENG-E2 125 Microgram/300 Microgram vs Placebo: serious adverse events | 0 of 13 | 0 of 11 | 24 | NCT02668783 | Trial comparisons |
| ENG 125 μg + E2 300 μg (MK-8342B) vs Placebo: Number of Participants Who Discontinued Study Treatment Due to an AE | 0 of 9 | 0 of 9 | 18 | NCT02668822 | Trial comparisons |
| ENG 125 μg + E2 300 μg (MK-8342B) vs Placebo: Number of Participants Who Experienced an Adverse Event (AE) | 0 of 9 | 1 of 9 | 18 | NCT02668822 | Trial comparisons |
| ENG 125 μg + E2 300 μg (MK-8342B) vs Placebo: serious adverse events | 0 of 9 | 0 of 9 | 18 | NCT02668822 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/HP_0100607/comparisons